Trial Profile
Obinutuzumab, Ibrutinib, and Venetoclax for Relapsed and Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 15 Jan 2024
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Obinutuzumab (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- 10 Jan 2024 Planned End Date changed from 29 Aug 2023 to 31 Dec 2024.
- 10 Jan 2024 Planned primary completion date changed from 29 Aug 2023 to 31 Dec 2024.
- 16 Nov 2022 Planned primary completion date changed from 29 Aug 2022 to 29 Aug 2023.